Category: Brandpoint Health

2018-10-11T16:29:00

(BPT) – Jennifer Hoodless was in the prime of her life (37) when she was diagnosed with Stage 3 classical Hodgkin lymphoma, a cancer that can affect younger people. A schoolteacher, wife, and mother of five young children who prided herself on living a healthy life, Jennifer was shocked when she learned of her disease.

“My Stage 3 diagnosis came out of nowhere,” Jennifer noted. “Our family lived a very active life and the idea that cancer could strike any one of us came as a true shock.” Jennifer’s diagnosis occurred in her early adulthood, which is not just the time when Hodgkin lymphoma is most common, but also a time in many people’s lives when they are managing daily stresses, such as college and new families, in addition to new challenges of coping with the diagnosis and subsequent treatment.

Hodgkin lymphoma starts in lymphocytes, which are white blood cells that comprise a large part of the body’s lymphatic system — a part of the immune system that helps fight infections and diseases. According to the American Cancer Society, an estimated 8,500 cases of Hodgkin lymphoma will be diagnosed in the United States this year, with approximately 1,050 of those cases resulting in death. Hodgkin lymphoma can affect people of all ages, and while it is most common in early adulthood, the risk of developing Hodgkin lymphoma also rises again later in life (after age 55).

Until recently, treatment for newly diagnosed Stage 3 or 4 Hodgkin lymphoma patients hadn’t changed in more than 40 years. In March 2018, ADCETRIS^® (brentuximab vedotin) for injection was approved by the U.S. Food and Drug Administration for adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma in combination with chemotherapy. Stage 3 and Stage 4 classical Hodgkin lymphoma is also called advanced stage Hodgkin lymphoma; this means that the cancer is more widespread throughout the body and may be present in organs outside the lymphatic system.

ADCETRIS represents important progress in treatment options for people like Jennifer. After noticing enlarged lymph nodes in her abdomen and on her neck, Jennifer was referred to Joseph M. Connors, M.D., FRCPC, Clinical Director, Center for Lymphoid Cancer at BC Cancer in Vancouver, Canada, who told her she was a candidate for a clinical trial testing ADCETRIS in combination with chemotherapy in patients with newly diagnosed advanced stage classical Hodgkin lymphoma. The clinical trial, called ECHELON-1, evaluated a combination of ADCETRIS and three chemotherapies, adriamycin, vinblastine, and dacarbazine (AVD), against a standard chemotherapy regimen of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).

“When I enrolled in this clinical trial, I was scared but determined to beat my cancer,” said Jennifer. “I persevered through side effects and I am thankful to be in remission now and back to work, with a thriving family and lots to look forward to.”

Historically, newly diagnosed patients with Hodgkin lymphoma have been treated with a chemotherapy regimen that includes bleomycin, an agent that can cause unpredictable and sometimes fatal lung toxicity. While ADCETRIS in combination with chemotherapy is bleomycin-free, there are side effects including possible lung toxicity, low numbers of red blood cells, low numbers of white blood cells, tingling or numbness in the hands or feet, constipation, vomiting, diarrhea, fever, weight loss, mouth sores, and abdominal pain. Please read the Important Safety Information, including BOXED WARNING, below.

“ADCETRIS in combination with chemotherapy marks an important advance in treatment for newly diagnosed advanced-stage classical Hodgkin lymphoma patients who are often young and have their whole lives ahead of them,” said Dr. Connors. “As an oncologist, it is exciting to see a treatment that fills an unmet need and can help improve patient prognosis.”

ADCETRIS Indication

ADCETRIS^® (brentuximab vedotin) for injection is approved for the treatment of:

• Previously untreated Stage 3/4 classical Hodgkin lymphoma (cHL): Adult patients with previously untreated Stage 3/4 cHL in combination with chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important serious safety information I should know about ADCETRIS?

• PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients who are treated with ADCETRIS can have a rare, serious infection of the brain called PML. It can cause death. Symptoms started at different times after starting ADCETRIS treatment, some within 3 months after the first dose. Other possible causes of PML are prior treatments or diseases that weakened the patient’s immune system.

• ADCETRIS should not be taken with bleomycin because of possible side effects in the lungs.

What are the other possible serious side effects of ADCETRIS?

• Nerve damage: Peripheral neuropathy (nerve damage) that mostly involves numbness or tingling in the hands or feet (sensory) and/or weakness in the arms or legs (motor). Symptoms increase with more doses. Your doctor may change or stop your ADCETRIS dose depending on the severity of your symptoms.

• Allergic and infusion reactions: Allergic reactions, including severe forms, during infusion or up to 24 hours after administration of ADCETRIS. Patients who had a reaction with earlier doses should receive premedication with later doses, which may include acetaminophen, an antihistamine, and a corticosteroid.

• Blood problems: Serious cases, including deaths, of fever with a low number of white blood cells have occurred with ADCETRIS. ADCETRIS may also cause a low number of white blood cells lasting a week or more, with or without fever. A low number of platelets (which help the blood clot) or red blood cells has also occurred with ADCETRIS.

Your doctor will give you a medicine called growth factor with your first dose if you are receiving ADCETRIS in combination with chemotherapy to treat Stage 3 or 4 cHL. Growth factor is meant to prevent you from having a low number of white blood cells.

Your blood counts will be checked before each dose, more often if necessary. You will be monitored for fever. If your white blood cell count is too low, your doctor may delay your next infusion, lower your dose, stop your ADCETRIS therapy, or give you growth factor with future doses of ADCETRIS.

• Infections: Serious infections, including deaths, that occur when your immune system is weakened, such as pneumonia, bacteremia, and sepsis or septic shock.

• Tumor lysis syndrome (TLS): You will be closely monitored for TLS if you have a tumor that grows quickly or have many tumor cells throughout your body.

• Patients with severe kidney disease may have more side effects and deaths compared to patients with normal kidney function and should avoid use of ADCETRIS.

• Patients with moderate or severe liver disease may have more side effects and deaths compared to patients with normal liver function and should avoid use of ADCETRIS.

• Liver injury: Serious liver problems, including deaths, have been reported after the first dose of ADCETRIS and after ADCETRIS was stopped and restarted. Your liver function will be monitored. Having liver problems, raised liver enzymes, and some medicines may increase the risk. Your doctor may delay your next infusion, lower your dose, or stop your ADCETRIS therapy if you have liver problems.

• Lung problems: Serious lung problems, including deaths, have been reported. If you have symptoms, your doctor may hold your ADCETRIS therapy until they improve.

• Skin problems: Rare but serious skin conditions, including deaths, called Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If either occurs, your doctor will stop ADCETRIS and treat you for symptoms.

• Gastrointestinal (GI) problems: Serious problems, including deaths, related to the pancreas, stomach, intestine, and colon have been reported. Lymphoma that involves the stomach or intestine may increase the risk of GI perforation (hole in the stomach or intestine).

• Fetal harm: ADCETRIS can harm a fetus (unborn baby). Women should not become pregnant while taking ADCETRIS and for at least 6 months after the last dose of ADCETRIS.

What were the most common side effects in the study?

In the 662 patients treated with ADCETRIS + chemotherapy, the most common side effects were low numbers of red blood cells, low numbers of white blood cells, tingling or numbness in the hands or feet, constipation, vomiting, diarrhea, fever, weight loss, mouth sores, and abdominal pain.

What should I tell my doctor before I start treatment with ADCETRIS?

• Tell your doctor about all of your medical conditions. ADCETRIS should be avoided if you have severe kidney disease or moderate or severe liver disease.
• Tell your doctor about any medicine you are taking (including over-the-counter drugs, vitamins, and herbal supplements) because it is possible for ADCETRIS to interact with certain types of drugs.
• Tell your doctor if you are pregnant or plan to become pregnant. You should not take ADCETRIS while pregnant or breastfeeding.
• Women should use effective birth control while taking ADCETRIS and for at least 6 months after the final dose of ADCETRIS.
• Men with female partners should use effective birth control while taking ADCETRIS and for at least 6 months after the final dose of ADCETRIS.

Contact your doctor if you experience any of the following:

• Symptoms of nerve damage: Tingling, burning, or numbness in the hands or feet. Changes in sense of touch or trouble moving the hands or feet.
• Symptoms of infection: Fever of 100.5°F or higher, chills, cough, or pain upon urination.
• Symptoms of infusion reaction: Fever, chills, rash, or breathing problems within 24 hours of infusion.
• Symptoms of liver injury: Fatigue, anorexia, upper stomach pain, dark urine, yellowing of the skin and eyes (jaundice).
• Symptoms of PML: Changes in mood or usual behavior. Confusion, thinking problems, or loss of memory. Changes in vision, speech, or walking. Decreased strength or weakness on one side of the body.
• Symptoms of lung problems: New or worsening cough or shortness of breath.
• Symptoms of acute pancreatitis: Severe abdominal pain.
• Symptoms of GI problems: Severe stomach pain, chills, fever, nausea, vomiting, or diarrhea.
• Pregnancy: Pregnant or breastfeeding women should not receive ADCETRIS. ADCETRIS can harm a fetus (unborn baby).
• Any other side effects that are bothersome or do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch/ or call 1-800-FDA-1088.

Please click here for full Prescribing Information, including BOXED WARNING.

2018-10-11T07:01:00

(BPT) – Within the sea of pink for National Breast Cancer Awareness Month, there is a wealth of information about early diagnosis, the newest treatments, and how to find support for a loved one who might be affected by the disease. While this information is critical, it is equally important that we recognize the 155,000 people living with metastatic breast cancer (MBC), the most advanced form of the disease. MBC is when the cancer has spread beyond the breast and nearby lymph nodes to other parts of the body such as the brain or the bones. It is important that MBC patients receive information relevant to them and that they are empowered to take an active role in their treatment in order to receive the best possible care.

Fortunately, patient advocacy groups, along with educational programs such as AstraZeneca’s Beyond Pink, offer education and support specifically for the unique needs of MBC patients and their loved ones. These groups help MBC patients and their families better understand what MBC is and provide education that aids in making informed decisions.

An important part of this decision-making is knowing the status of your tumor. Tumor testing — testing to understand whether your tumor is hormone receptor-positive or negative and whether it expresses too much of the human epidermal growth factor receptor 2 (HER2) protein — is particularly important for those with MBC. For these patients, knowing the tumor status may help determine how their cancer is treated as some treatments are designed to treat certain types of tumors. Additionally, it is important that patients discuss with their physician the need to retest their tumor as the status of the tumor can change over time. Some patients may also want to discuss with their doctor the possibility of genetic testing to learn if their cancer was caused by an inherited genetic mutation.

“Risk factors of an inherited genetic mutation may include triple-negative breast cancer, cancer in both breasts, multiple cancers in the family, including breast and ovarian cancers, cases of male breast cancer and Ashkenazi Jewish ethnicity, although some people with an inherited mutation may not have a family history,” said Dr. Sue Friedman, Founder and Executive Director of Facing Our Risk of Cancer Empowered (FORCE). “For those considered at risk of an inherited genetic mutation, it is important to discuss your options with a genetics expert to determine if testing is right for you, as knowing your BRCA status plays an important role in determining the best treatment path.”

“A metastatic breast cancer diagnosis is scary, and people naturally have a lot of questions,” said Jean Sachs, Chief Executive Officer of LBBC. “MBC patients are likely to be on treatment for the rest of their lives, so it’s important that they receive accurate and complete information and find a community to help them navigate their journey. It is also important for patients to be their own advocate and take an active role in their treatment by asking questions and communicating with their health care team.”

Resources to help you play an active role in your treatment decisions can be found on the Beyond Pink: Sharing Our Metastatic Breast Cancer Story campaign website. Since its inception in 2015, the Beyond Pink campaign has developed a variety of tools to help support people living with MBC, as well as their caregivers. Additionally, the Beyond Pink Experience Center has hosted events throughout the US to help broaden the breast cancer conversation through education and patient experience. To date, we’ve welcomed more than 4,700 people to the Beyond Pink Experience Center at local events and look forward to continuing to reach the MBC community in the year ahead.

Throughout October, support those living with MBC by using the #BeyondPink and #NBCAM hashtags on Twitter and Facebook and visiting LifeBeyondPink.com.

2018-10-10T11:29:00

(BPT) – Atopic dermatitis, also known as eczema, is a skin condition that may affect people of all races and ethnicities, but may occur more frequently in African-American children.^[1] According to US research, 19.3 percent of African-American children have eczema compared to 16.1 percent of European-American children.^[1] There are many different treatment options available to consider when taking into account the unique characteristics of each patient. Here are some facts to help understand eczema.

1. Eczema may present itself differently on everybody. Eczema commonly appears as dry, scaly, or red skin, and is often accompanied by oozing, crusted bumps; however, it may appear differently on different people.^[1],[2],[3] The face, neck, wrists, and ankles are common sites for many people, depending on age. Places where your body bends—like your elbows or back of your knees—are also common areas affected.^[2] For those of African descent, eczema may be more prevalent on the outer parts of the arms and legs.^[1] It is important to understand that eczema can also lead to issues such as dyspigmentation, which is skin discoloration that may be more apparent on darker skin tones.^[4]

2. Stay moisturized and avoid triggers. It is important to know what works best for your skin. Moisturizers, such as creams, ointments, oils, gels, and lotion can help keep your skin moisturized.^[5] Typical eczema triggers may include irritants (soaps, detergents, sweat, and rough fabrics), allergens (some types of food, dust mites, pollens), and environmental (temperature extremes, high or low humidity).^[2],[5] It may be helpful to track your flares in a notebook to help guide your conversation with your doctor.

3. Connect with the community for support. A large community of people living with or caring for someone with eczema is only a few clicks away on social media. Platforms such as Facebook and Instagram allow people living with the skin disease to find support, connect with other patients, and share their own personal stories.

4. Talk to your doctor about your options. It is important to discuss available treatment options with your doctor. EUCRISA^® (crisaborole) ointment, 2% is a steroid-free treatment for mild-to-moderate eczema in adults and kids as young as two. EUCRISA can be used on all skin tones.^[6]

EUCRISA is a topical treatment that can be used nose to toes. EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth or vagina. It works above and below the skin to treat eczema. The active ingredient in EUCRISA is crisaborole 2%, which acts deep within skin cells to target phosphodiesterase 4 (PDE4).^[6] PDE4 is an enzyme that helps to regulate inflammation in your body. When you have eczema, PDE4 enzymes may be overactive in your skin cells. This can lead to inflammation in your skin. Reducing PDE4 activity decreases substances in your skin that are thought to cause inflammation related to eczema.^[7],[8],[9] The specific way EUCRISA works is not well defined.^[6]

Crisaborole is combined with an Emollient-Rich Vehicle ointment. Ointments contain emollients, which can help lock in moisture and soften the skin.^[6],[10]

IMPORTANT SAFETY INFORMATION & INDICATION

Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA.

EUCRISA may cause side effects including allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. If you have any of these symptoms, stop using EUCRISA and get medical help right away.

The most common side effect of EUCRISA is application site pain, such as burning or stinging.

EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth, or vagina.

INDICATION

EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and children 2 years of age and older.

See Full Prescribing Information at EUCRISA.com.

The information above, along with the treatment regimen that you and your doctor decide upon, may help provide a better understanding of your eczema. If you have additional questions, be sure to speak with your doctor.

For more information about EUCRISA, visit www.EUCRISA.com or call 1-866-EUCRISA (1-866-382-7472).

The EUCRISA Copay Savings Card is now available for eligible patients for as little as $10.* You can receive your card by texting EOFFER4 to 42762 or by visiting our website: https://www.eucrisa.com/eucrisa-4-you.

By opting into the EUCRISA mobile program, you consent to receive up to 10 marketing or not-marketing text messages and/or push notifications per month from Pfizer Inc., such as refill reminders, fill confirmation and website information.

*See terms and conditions. Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $700 per tube. Annual savings up to $2,800. This Card will be accepted only at participating pharmacies. This Card is not health insurance.

Eucrisa.com 1-866-382-7472 Pfizer Inc. PO Box 29387, Mission, KS 66201

This article is sponsored by Pfizer Inc.

PP-CRI-USA-1498

###

---

[1] Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups- variations in epidemiology, genetics, clinical presentation and treatment. Experimental Dermatology. 2018;27:340-357.

[2] Bieber T. Atopic dermatitis. Dermatol. 2012;1(3):203-217.

[3] Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allerg Clin Immunol. 2006;118:152-169.

[4] Siegfried EC, Hebert AA. Diagnosis of atopic dermatitis: mimics, overlaps and complications. J Clin Med. 2015;4(5):884-917.

[5] Oszukowska M, Michalak I, Gutfreund K, et al. Role of primary and secondary prevention in atopic dermatitis. Postep Derm Alergol. 2015;32(6):409-420.

[6] EUCRISA^® (crisaborole). Full Prescribing Information. October 2017.

[7] Jarnagin K, Chanda S, Coronado D, Ciaravino V, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390-396.

[8] Chan SC, Reifsnyder D, Beavo JA, Hanifin JM. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol. 1993;91(6):1179-1188.

[9] Sawai T, Uehara M. Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correction with respiratory atopy. Br J Dermatol. 1998;138(5):846-848.

[10] Eichenfield LF, Tom WL, Berger TG, Krol A, et al. Guidelines of care for the management of atopic dermatitis. Section 2: management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.

2018-10-10T09:01:00

(BPT) – People living with type 1 diabetes (T1D) are faced with daily challenges like stress and limited freedom to do what they love, leaving them seeking additional ways to help manage their condition. This sentiment is shared by medical professionals, specifically endocrinologists who want to do more to help their patients living with T1D.

In two recent online T1D Unmet Needs surveys from the American Association of Clinical Endocrinologists (AACE), conducted by The Harris Poll in collaboration with Sanofi US and Lexicon Pharmaceuticals, more than 70 percent of adults living with T1D (73%) and endocrinologists (73%) stated that recent advances in T1D care give them hope that there will eventually be a cure. However, according to the surveys, an overwhelming majority (87% of adults with T1D; 93% of endocrinologists) agreed that more advances are needed to help improve the lives of those with the disease.

Some of the results of this survey may be surprising, including that many adults living with T1D:

* feel like the whole day revolves around managing the disease (51%)

* feel like a burden to their partner (35%)

* avoid going out to eat (57%)

* avoid attending social gatherings with family and friends (49%)

The Challenge of Life with T1D is Ongoing

For those living with T1D, everyday situations that other people take for granted can be challenging and can ultimately have an adverse impact on their lives. For instance, adults living with T1D have a significant emotional burden: 88 percent said living with the disease adds stress to their lives, and 55 percent said managing their T1D takes up a significant amount of time and energy.

These challenges extend into disease management as well, as adults living with T1D also said they struggle the most with keeping their blood sugar within the recommended range (58%) and achieving individualized target A1C levels (48%). In addition, approximately 77 percent of adults living with T1D stated they wish they had medications to help them stay within the recommended blood sugar range for longer periods of time.

Opportunities Exist to Improve Education and Prioritize Better Outcomes

Overall, the survey results illuminated the T1D community’s need for more than what is currently available in terms of support, management and treatment of the disease and why it is important to continue prioritizing and advancing innovation to help people achieve better outcomes. Living with T1D is an everyday challenge, so it may not be surprising that 96 percent of endocrinologists and 88 percent of adults living with T1D are hopeful that future advances in T1D will help with overcoming the challenges of this disease.

In combination with bringing to light the unresolved needs of this community, these results represent an opportunity to enhance education that might ultimately help improve T1D care and outcomes. Learning more about the condition is an important step toward addressing the challenges that people living with T1D face daily. The findings of this survey will also hopefully help to encourage further dialogue and information-sharing between endocrinologists and their patients. For more information on the challenges of living with T1D, please visit gobeyondinsulinalonet1d.com.

About the surveys

The research was conducted online by The Harris Poll on behalf of the American Association of Clinical Endocrinologists (AACE) in collaboration with Lexicon Pharmaceuticals Inc. and Sanofi, among patients diagnosed with type 1 diabetes (T1D) and endocrinologists who treat T1D patients within the United States. The patient survey was conducted May 21 through June 6, 2018 among 255 adults age 18+ who have been diagnosed with T1D by a healthcare professional. Figures for age by gender, income, race/ethnicity, region, size of household, marital status and employment status were weighted where necessary to bring them into line with their actual proportions in the population. The healthcare professional survey was conducted May 22 through June 11, 2018, among 253 endocrinologists who see at least one patient with T1D in a month. Results were weighted for gender, by years in practice, and by region where necessary to bring them into line with their actual proportions in the population.

SAUS.SOTA.18.07.4134

2018-10-08T09:01:00

(BPT) – More than one-third of adults in the United States have obesity, which is associated with some of the leading causes of death, including diabetes, heart disease, stroke and some types of cancer.^[1]

If you have obesity and feel like you’ve tried everything to lose weight, you may be ready to consider bariatric surgery, also known as weight loss surgery. Of the more than 25 million surgically eligible people in the United States, less than one percent have weight loss surgery each year.^[2]

Deciding to have weight loss surgery can be challenging, as can sustaining your new lifestyle, but it can also be rewarding — and you don’t need to do it alone.

Here are three things to know as you explore your treatment options and physically, mentally and emotionally prepare for weight loss surgery and recovery.

1. The decision is complex and different for everyone.

Losing weight, and sustaining it, can help people become healthier and live fuller and more active lives. Your decision and reason to have weight loss surgery is personal, and making the decision can be emotional and challenging for both you and your loved loves. While it can be overwhelming, it’s important to explore your options before deciding. With the right support and information, you can feel confident about your path forward.

Only you and your bariatric surgeon can determine if, and which, weight loss surgery is right for you, and only you can determine if you are ready for it. However, if you are ready to explore your options, TheHealthPartner.com can provide the support you need, including science-based information about the benefits and types of weight loss surgery, stories from people who have gone through the full journey of considering options and pursuing surgery, and assistance finding a specialist.

2. It requires physical, mental and emotional preparation.

Before your surgery, you will meet with your care team, including your surgeon and specialists such as psychologists and dietitians, to create a diet and exercise plan and prepare you for your new lifestyle after surgery. To prepare yourself mentally and emotionally, it is helpful to organize a support network which might include family, friends or others who may have been through weight loss surgery and experienced and overcome many of the same fears.

Once you have scheduled your surgery, the Health Partner for Weight Loss Surgery app can help provide personalized guidance as you prepare for surgery along with your surgeon and medical team. Key features include a customizable action plan to track appointments and take steps to prepare physically and emotionally, as well as real life stories from patients who have undergone surgery and educational resources so you know what to expect. The app is available on the App Store and Google Play.

3. It’s a journey, not a destination.

Weight loss surgery is not a one-time action; it is a life-long commitment. Sustaining your weight loss after surgery requires breaking old habits and working hard to create and sustain new ones. While you may not always feel as motivated to eat healthy and exercise regularly as when you first began your journey, following your doctor’s care plan will help you transition into your new lifestyle.

The Health Partner for Weight Loss Surgery app can help assist you to follow your doctor’s recommendations by tapping into what motivates and drives you as an individual to get and stay healthy after surgery, and providing reminders and integration with your tracking apps to monitor your progress.

Weight loss surgery can be daunting, but Johnson & Johnson Health Partner can support you every step of the way. Start your journey today by visiting TheHealthPartner.com.

---

2018-10-08T09:01:00

(BPT) – Have you been experiencing chronic pain in your knees or hips? Is it making everyday activities like walking or getting out of bed a challenge? You’re not alone.

Osteoarthritis, also known as OA, impacts more than 30 million adults in the United States and is one of the most common reasons a person will need a joint replacement, according to the US Centers for Disease Control and Prevention.^[1]

If the pain is interfering with your day-to-day life, and treatments like medication or physical therapy aren’t providing relief, knee or hip replacement surgery may be right for you.

Ask yourself these three questions and learn more about how you can explore your treatment options and physically, mentally and emotionally prepare for knee or hip replacement surgery and recovery.

1. Is knee or hip replacement surgery right for me?

Knee or hip replacement surgery is not about age. When pain prevents you from being active, or if you’re no longer responding to other types of treatment, it may be time to talk to your doctor about surgery. Knee or hip replacement surgery can provide relief from pain and stiffness, improve mobility and give you the freedom to do what you love again.

Only an orthopedic surgeon can determine if knee or hip replacement surgery is right or you, and only you can determine if you are ready for it. However, if you are ready to explore your options, TheHealthPartner.com can provide the support you need, including science-based information personalized to your level of pain and assistance finding an orthopedic specialist.

2. How do I prepare for knee or hip replacement surgery?

Preparing for knee or hip replacement surgery can include getting in better physical shape to lessen the chance for complications and minimize your recovery time, and making caregiver arrangements for a smooth rehabilitation.

Once you have scheduled your surgery, the Health Partner for Knees & Hips app can provide personalized guidance as you prepare for surgery. Key features include a customizable action plan to track appointments and take steps to prepare physically and emotionally, as well as real life stories from patients who have undergone surgery and educational resources so you know what to expect. The app is available on the App Store and Google Play.

3. What should I expect after knee or hip replacement surgery?

Returning to normal activity after knee or hip replacement surgery typically takes a few months. Following the care plan set forth by your doctor is extremely important in helping ensure a successful recovery and helping restore the strength in your muscles and movement in your joints.

The Health Partner for Knees & Hips app can help make it easier for you to follow your doctor’s recommendations by tapping into what motivates and drives you as an individual to get and stay healthy after surgery, and providing reminders and integration with your tracking apps to monitor your progress.

Knee and hip replacement surgery can be daunting, but Johnson & Johnson Health Partner can support you every step of the way. Start your journey today by visiting TheHealthPartner.com.

---

2018-10-04T16:21:00

(BPT) – Growing up, Roberto Novelli wore a helmet every day until he was 4 years old. His parents were very protective after he was diagnosed with a bleeding disorder called hemophilia A at just 2 months old. To manage his disorder, he received three infusions of treatment into his veins each week to try to prevent bleeds.

Living with hemophilia A means a person’s blood does not clot properly, which can result in bleeds in the muscles and joints that may lead to joint damage and chronic pain.^[1] For some, even a single joint bleed can cause long-term damage.^[2] Roberto isn’t alone — about 20,000 Americans have hemophilia, with hemophilia A being the most common form.^[3]

“Before I got to high school, my parents didn’t want me playing sports or being too active. They were so worried about me getting a serious bleed,” he said. “It really impacted my life growing up.”

Roberto, now 26, is an academic advisor at the University of Michigan-Dearborn, a graduate student and an avid outdoor enthusiast who spends much of his free time kayaking.

In 2017, Dr. Michael Callaghan, a hematologist at Children’s Hospital of Michigan, recommended Roberto join a clinical trial for Hemlibra^® (emicizumab-kxwh), which was being studied as a prophylactic (preventative) treatment for people with hemophilia A.

“When Dr. Callaghan mentioned trying Hemlibra to me, I’ll admit I was nervous — why mess with what you’ve been doing for so long?” Roberto said. “But I’m glad I took the opportunity to join the clinical trial. With Hemlibra, I’ve had fewer bleeds, and I’m proud to have played a role in making this medicine available for other people with hemophilia A.”

In October 2018, the U.S. Food and Drug Administration (FDA) approved Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors. Hemlibra is now the first and only approved medicine for hemophilia A, with or without factor VIII inhibitors, that can be self-administered under the skin (subcutaneously) and only once weekly, every two weeks or every four weeks.

“The approval of Hemlibra is an important advancement for the entire hemophilia A community,” Dr. Callaghan said. “For the first time in nearly 20 years, people with hemophilia A, like Roberto, have a new class of medicine. Hemlibra can reduce bleeds, while offering a new subcutaneous administration and multiple dosing options.”

Positive results from the clinical trial Roberto joined showed Hemlibra prophylaxis significantly reduced treated bleeds compared to no prophylaxis treatment in people with hemophilia A without factor VIII inhibitors, and 55.6 percent of people taking Hemlibra every week had zero bleeds after 24 weeks compared to 0 percent of people receiving no prophylaxis treatment. Additionally, Hemlibra is the first medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, which has been the recommended standard of care for people with hemophilia A without factor VIII inhibitors, as demonstrated by a statistically significant reduction of 68 percent in treated bleeds in an intra-patient comparison.

Hemlibra increases the potential for blood to clot. Patients should carefully follow their healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. Hemlibra may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA^®), including thrombotic microangiopathy (TMA) and blood clots (thrombotic events). If aPCC (FEIBA^®) is needed, patients should talk to their healthcare provider in case they feel they need more than 100 U/kg of aPCC (FEIBA^®) total. Hemlibra may interfere with laboratory tests that measure how well a patient’s blood is clotting and may cause a false reading.^[4]

“Taking Hemlibra once a week reduced the amount of time I spent treating my hemophilia A — it was a meaningful milestone,” Roberto said. “Because of that, I have more time to do other things. This summer I went to Michigan’s Pictured Rocks and Kensington Metropark, and I spent more time outdoors and kayaking and less time taking my medicine.”

Everyone is different and each individual’s experience may vary. For more information about hemophilia A with or without factor VIII inhibitors and Hemlibra, visit www.hemlibra.com and talk to your doctor.

Please see the Hemlibra full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.

Patient Indication and Safety Information

Hemlibra is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information to know about Hemlibra?

Hemlibra increases the potential for blood to clot. Patients should carefully follow their healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. Hemlibra may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA^®), including:

• Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to one’s kidneys, brain, and other organs. Patients should get medical help right away if they have any of the following signs or symptoms during or after treatment with Hemlibra:

confusion	stomach (abdomen) or back pain
weakness	nausea or vomiting
swelling of arms and legs	feeling sick
yellowing of skin and eyes	decreased urination

• Blood clots (thrombotic events). Blood clots may form in blood vessels in the arm, leg, lung, or head. Patients should get medical help right away if they have any of these signs or symptoms of blood clots during or after treatment with Hemlibra:

swelling in arms or legs	feel faint
pain or redness in the arms or legs	headache
shortness of breath	numbness in the face
chest pain or tightness	eye pain or swelling
fast heart rate	trouble seeing
cough up blood

If aPCC (FEIBA^®) is needed, patients should talk to their healthcare provider in case they feel they need more than 100 U/kg of aPCC (FEIBA^®) total.

Before using Hemlibra, patients should tell their healthcare provider about all of their medical conditions, including if they:

• are pregnant or plan to become pregnant. It is not known if Hemlibra may harm an unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with Hemlibra.
• are breastfeeding or plan to breastfeed. It is not known if Hemlibra passes into breast milk.

Patients should tell their healthcare provider about all the medicines they take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Patients should keep a list of them to show their healthcare provider and pharmacist when they get a new medicine.

How should patients use Hemlibra?

Patients should see the detailed “Instructions for Use” that comes with Hemlibra for information on how to prepare and inject a dose of Hemlibra, and how to properly throw away (dispose of) used needles and syringes.

• Stop (discontinue) prophylactic use of bypassing agents the day before starting Hemlibra prophylaxis.
• Patients may continue prophylactic use of factor VIII for the first week of Hemlibra prophylaxis.

What should patients know about lab monitoring?

Hemlibra may interfere with laboratory tests that measure how well blood is clotting and may cause a false reading. Patients should talk to their healthcare provider about how this may affect their care.

The most common side effects of Hemlibra include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain.

These are not all of the possible side effects of Hemlibra. Patients should speak to their healthcare provider for medical advice about side effects.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Patients should not use Hemlibra for a condition for which it was not prescribed. Patients should not give Hemlibra to other people, even if they have the same symptoms that they have. It may harm them. Patients can ask their pharmacist or healthcare provider for information about Hemlibra that is written for health professionals.

Side effects may be reported to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Side effects may also be reported to Genentech at (888) 835-2555.

Please see the Hemlibra full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.

2018-10-03T17:25:00

(BPT) – The opioid crisis has made physicians increasingly wary about prescribing the potentially addictive drugs to their patients in pain. Experts in pain medicine, such as physician anesthesiologists, are creating individualized pain management plans that include alternatives to opioids that are not only safer, but often work better.

“Opioids, or narcotics, can be helpful for short-term relief, but they are not a long-term solution for managing pain because of their many downsides, from significant side effects to a high risk of dependence or addiction,” said Greg L. Thompson, M.D., physician anesthesiologist, pain medicine specialist and member of the American Society of Anesthesiologists (ASA). “Pain medicine specialists can help people in pain get relief and reduce or eliminate opioids often by using a combination of techniques from physical therapy and nerve blocks to non-addictive pain medications.”

Opioids alleviated the excruciating pain 37-year-old mother of two Beth Hunt suffered while recovering from multiple surgeries after her leg was crushed in an accident. But after three months in the hospital on opioids, she came to rely on them just to be comfortable. Hunt turned to Dr. Thompson, who used ultrasound and tiny catheters, or tubes, to direct medication to the major nerves in her leg that were the source of the pain. This therapy reduced her opioid use by 90 percent while her leg healed, and she learned to walk again. Now she is opioid-free, has regained her quality of life and is spending time being active with her children.

Hunt never dreamed she’d become dependent on opioids, but her experience shows it can happen to anyone. ASA urges people to learn how the opioid crisis is changing the way physicians treat pain responsibly, and the reasons your physician may limit or avoid prescribing opioids:

They are not the only option:

While opioids can provide general pain relief for a short while, they are not the solution for all pain because:

* There are more effective methods for treating pain in a specific site, including nerve blocks or stimulation therapy.

* People who take them can begin tolerating the dose and may need higher doses to get the same relief.

There are many side effects and risks:

* Addiction and dependence are major worries. If there are signs of risk for addiction your physician may be more hesitant to prescribe opioids.

* Other side effects include: sleepiness, constipation, depression, life-threatening shallow breathing and slowed heart rate — which could be a sign of an overdose.

* In older people, opioids can increase the risk of falling as well as interact with other medications, making them less effective or causing side effects.

It’s the law:

Legislators have enacted many rules and regulations to stem the opioid crisis. For example, because studies show the longer people take opioids, the more likely they are to become addicted, some states have enacted prescribing limits on opioids.

It’s important to know there are many other options for managing pain, from targeted therapies (e.g., nerve blocks) to non-addictive medications (e.g., antidepressants, antiseizure medications, acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen) to high-tech methods (e.g., spinal stimulation and radiowave therapy) to alternative treatments (e.g., physical therapy, acupuncture and meditation).

For more information on pain treatment, visit the American Society of Anesthesiologists online at asahq.org/pain or find them on Facebook and Twitter. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount.

2018-10-03T09:21:00

(BPT) – More than 9 out of 10 generic drug prescriptions are filled for $20 or less. Everybody who takes medicine to get or stay healthy can appreciate these savings, which allow patients and families to spend their money on other things that matter to them. Those savings, however, are now in jeopardy, thanks to a combination of factors. Here’s what you need to know.

2018-10-02T09:01:24

(BPT) – This week, the Centers for Disease Control and Prevention (CDC) is shining the spotlight on a topic we usually shy away from: fungus. October 1^st through 5^th is the CDC’s Fungal Disease Awareness Week, bringing attention to fungal diseases and the importance of their early recognition, diagnosis, and treatment. As Fungal Disease Awareness Week focuses on a broad range of infections, it’s important to recognize the ways that fungal disease can affect even the smallest parts of the body – right down to the tips of the toes.

In fact, as many as 35 million Americans – nearly 11 percent of the U.S. population – suffer from toenail fungus.^1,2

In recognition of Fungal Disease Awareness Week, here are some of the key facts to know about toenail fungus:

• Anyone can get toenail fungus, but age, health and lifestyle can put you at greater risk. Patients with weakened or suppressed immune systems due to illness or medication and those with poor circulation or diabetes are at increased risk³
• Early stage forms of toenail fungus are usually painless, but if the fungus is left to grow and worsen, it can become painful, especially when wearing shoes³
• Permanent toenail damage is a complication of a fungal infection, and serious infections can even spread beyond the toe⁴
• There are several different treatments for nail fungus, including antifungal pills, nail removal, and medicines applied to the nail³

When it comes to treatment, however, motivation and adherence are often key.

“For patients with toenail fungus, a long term treatment, which is typically a year due to how the nails grow, is important in treating the infection,” said Dr. Tracey Vlahovic, DPM, Professor, Department of Podiatric Medicine at Temple University. “To increase your chances of getting rid of toenail fungus for good, it’s important to keep all follow-up appointments with your healthcare practitioner and use your treatment as prescribed.”

One way to help ensure you stick with your treatment plan is by utilizing mobile apps to keep you on track. For patients using JUBLIA^® (efinaconazole) topical solution, 10% to treat their toenail fungus, the JubliApp mobile app is a helpful tool designed to help encourage compliance with treatment. The app offers treatment reminders, the ability to take photos and track your progress over time, and a game to keep patients engaged while the daily application is drying, helping to make the 48-week long therapy less intimidating. To download the app, visit the App Store on an iOS device or Google Play on an Android mobile device and search “JubliApp^TM” or “Jublia^®” and click “Get” to download.

To learn more about toenail fungus and potential treatment options, talk to your healthcare provider, and to read more about Fungal Disease Awareness Week, visit the CDC website. For more information about JUBLIA and complete prescribing information, visit https://www.jubliarx.com/.

Indication

JUBLIA^® (efinaconazole) Topical Solution, 10% is a prescription medicine used to treat fungal infections of the toenails.

Important Safety Information

• JUBLIA is for use on nails and surrounding skin only. Do not use JUBLIA in your mouth, eyes, or vagina. Use it exactly as instructed by your doctor.
• It is not known whether JUBLIA is effective in children.
• Before you use JUBLIA, tell your doctor about all your medical conditions, including if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed, because it is not known whether JUBLIA can harm an unborn fetus or nursing infant.
• Tell your doctor about all medications you are taking, and whether you have any other nail infections.
• JUBLIA is flammable. Avoid heat and flame while applying JUBLIA to your toenail.
• JUBLIA may cause irritation at the treated site. The most common side effects include: ingrown toenail, redness, itching, swelling, burning or stinging, blisters, and pain. Tell your doctor about any side effects that bother you or do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full prescribing information.

References

1. Joseph, W. et al. (2013). Onychomycosis and the Role of Topical Antifungals. Podiatry Today (supplement). Retrieved from https://www.podiatrytoday.com/files/Valeant_Supplement.pdf. Accessed September 7, 2018.
2. United States Census. U.S. and World Population Clock. Retrieved from https://www.census.gov/popclock/. Accessed September 7, 2018.
3. American Academy of Dermatology. Nail Fungus. Retrieved from https://www.aad.org/public/diseases/contagious-skin-diseases/nail-fungus#overview. Accessed September 6, 2018.
4. The Mayo Clinic. Nail Fungus. Retrieved from https://www.mayoclinic.org/diseases-conditions/nail-fungus/symptoms-causes/syc-20353294. Accessed September 6, 2018.

JUBLIA is a trademark of Ortho Dermatologics’ affiliated entities.

©2018 All Rights Reserved.

JUB.0148.USA.18